New York, March 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaccine Contract Manufacturing Industry" -
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.
Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.
Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.
Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.
for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.
Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.
Abstract:
- Global Vaccine Contract Manufacturing Market to Reach $4.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Vaccine Contract Manufacturing estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 8% over the analysis period 2020-2027. Attenuated, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$1.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Inactivated segment is readjusted to a revised 8.2% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $672.6 Million, While China is Forecast to Grow at 12.1% CAGR
- The Vaccine Contract Manufacturing market in the U.S. is estimated at US$672.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$960.8 Million by the year 2027 trailing a CAGR of 12% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.
- Subunit-based Segment to Record 8.4% CAGR
- In the global Subunit-based segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$280.9 Million in the year 2020 will reach a projected size of US$475.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$590.6 Million by the year 2027, while Latin America will expand at a 10% CAGR through the analysis period.
Select Competitors (Total 34 Featured) -
Ajinomoto Althea, Inc.
Albany Molecular Research, Inc.
Catalent, Inc.
Cobra Bio
Cytovance Biologics
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Icon plc
IDT Biologika
KBI Biopharma
Lonza
Read the full report:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Vaccine Contract Manufacturing Competitor Market Share Scenario
Worldwide (in %): 2020E
Global Competitor Market Shares by Segment
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Vaccine Contract
Manufacturing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Vaccine Contract
Manufacturing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Vaccine Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Attenuated by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Attenuated by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Attenuated by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Inactivated by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Inactivated by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 9: World 15-Year Perspective for Inactivated by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Subunit-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 11: World Historic Review for Subunit-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 12: World 15-Year Perspective for Subunit-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Toxoid-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 14: World Historic Review for Toxoid-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 15: World 15-Year Perspective for Toxoid-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for DNA-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 17: World Historic Review for DNA-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 18: World 15-Year Perspective for DNA-based by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Human by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 20: World Historic Review for Human by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 21: World 15-Year Perspective for Human by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Veterinary by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 23: World Historic Review for Veterinary by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for Veterinary by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
Market Analytics
Table 25: USA Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 26: USA Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 27: USA 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 28: USA Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 29: USA Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 30: USA 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
CANADA
Table 31: Canada Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 32: Canada Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 33: Canada 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 34: Canada Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 35: Canada Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 36: Canada 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
JAPAN
Table 37: Japan Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 38: Japan Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 39: Japan 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 40: Japan Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 41: Japan Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 42: Japan 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
CHINA
Table 43: China Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 44: China Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 45: China 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 46: China Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 47: China Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 48: China 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
EUROPE
Market Facts & Figures
Market Analytics
Table 49: Europe Current & Future Analysis for Vaccine Contract
Manufacturing by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 50: Europe Historic Review for Vaccine Contract
Manufacturing by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 51: Europe 15-Year Perspective for Vaccine Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 53: Europe Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 54: Europe 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 56: Europe Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 57: Europe 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
FRANCE
Table 58: France Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 59: France Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 60: France 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 61: France Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 62: France Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 63: France 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
GERMANY
Table 64: Germany Current & Future Analysis for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 65: Germany Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 66: Germany 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 67: Germany Current & Future Analysis for Vaccine
Contract Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 68: Germany Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 69: Germany 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
ITALY
Table 70: Italy Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 71: Italy Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 72: Italy 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 73: Italy Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 74: Italy Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 75: Italy 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 76: UK Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 77: UK Historic Review for Vaccine Contract Manufacturing
by Vaccine Type - Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 78: UK 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 79: UK Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 80: UK Historic Review for Vaccine Contract Manufacturing
by Application - Human and Veterinary Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 81: UK 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
SPAIN
Table 82: Spain Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 83: Spain Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 84: Spain 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 85: Spain Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 86: Spain Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 87: Spain 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
RUSSIA
Table 88: Russia Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 89: Russia Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 90: Russia 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 91: Russia Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 92: Russia Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 93: Russia 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 94: Rest of Europe Current & Future Analysis for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 95: Rest of Europe Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 96: Rest of Europe 15-Year Perspective for Vaccine
Contract Manufacturing by Vaccine Type - Percentage Breakdown
of Value Sales for Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based for the Years 2012, 2020 & 2027
Table 97: Rest of Europe Current & Future Analysis for Vaccine
Contract Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 98: Rest of Europe Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 99: Rest of Europe 15-Year Perspective for Vaccine
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Human and Veterinary for the Years 2012, 2020 &
2027
ASIA-PACIFIC
Table 100: Asia-Pacific Current & Future Analysis for Vaccine
Contract Manufacturing by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 101: Asia-Pacific Historic Review for Vaccine Contract
Manufacturing by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 102: Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Table 103: Asia-Pacific Current & Future Analysis for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 104: Asia-Pacific Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 105: Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Vaccine Type - Percentage Breakdown
of Value Sales for Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based for the Years 2012, 2020 & 2027
Table 106: Asia-Pacific Current & Future Analysis for Vaccine
Contract Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 107: Asia-Pacific Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 108: Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Human and Veterinary for the Years 2012, 2020 &
2027
AUSTRALIA
Table 109: Australia Current & Future Analysis for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 110: Australia Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 111: Australia 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 112: Australia Current & Future Analysis for Vaccine
Contract Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 113: Australia Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 114: Australia 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
INDIA
Table 115: India Current & Future Analysis for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 116: India Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 117: India 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 118: India Current & Future Analysis for Vaccine Contract
Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 119: India Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 120: India 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
SOUTH KOREA
Table 121: South Korea Current & Future Analysis for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 122: South Korea Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 123: South Korea 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2020 & 2027
Table 124: South Korea Current & Future Analysis for Vaccine
Contract Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 125: South Korea Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 126: South Korea 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Table 127: Rest of Asia-Pacific Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 128: Rest of Asia-Pacific Historic Review for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 129: Rest of Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Vaccine Type - Percentage Breakdown
of Value Sales for Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based for the Years 2012, 2020 & 2027
Table 130: Rest of Asia-Pacific Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 131: Rest of Asia-Pacific Historic Review for Vaccine
Contract Manufacturing by Application - Human and Veterinary
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR
Table 132: Rest of Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Human and Veterinary for the Years 2012, 2020 &
2027
LATIN AMERICA
Table 133: Latin America Current & Future Analysis for Vaccine
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report:
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
